A selection of major announcements

1. NIO receives a new round of strategic investment of 2.2 billion US dollars in the Middle East

$NIO-SW (09866.HK)$The Hong Kong Stock Exchange issued an announcement stating that a new round of share subscription agreements has been signed with Abu Dhabi investment agency CYVN Holdings (“CYVN”), and CYVN Holdings will make a total strategic investment of about 2.2 billion US dollars in NIO in the form of cash through its subsidiary CyVN Investments. Under the share subscription agreement, CYVN will subscribe for 294 million shares of the company's newly issued Class A common stock at a purchase price of $7.50 per share.

2. Kuaishou announces an automatic repurchase plan of HK$2.5 billion

$KUAISHOU-W (01024.HK)$The announcement stated that as part of the 4 billion Hong Kong dollar repurchase plan announced on May 22 this year, the company will automatically repurchase the company's shares on the open market from December 19 this year to May 24 next year, for a total amount not exceeding HK$2.5 billion.

3. CITIC Shares: Proposed spin-off of CITIC Deca and independent listing on the Shanghai Stock Exchange

$CITIC (00267.HK)$The Hong Kong Stock Exchange announced that it is proposed to spin-off CITIC Deca Co., Ltd., an indirect non-wholly owned subsidiary of the company, and its shares for independent listing on the Shanghai Stock Exchange. CITIC Deca is one of the world's largest manufacturers of aluminum auto parts. Its products include aluminum wheels and lightweight aluminum castings for automotive powertrains, chassis, and body systems. CITIC Industrial Investment Group Co., Ltd., an indirect wholly-owned subsidiary of the company, holds 42.11% interest in CITIC Deca.

4. Shiyao Group submitted a new drug marketing application to the US FDA

$CSPC PHARMA (01093.HK)$The announcement said that the Group has submitted to the US Food and Drug Administration (FDA) a new drug marketing application (NDA) for irinotecan liposomal injection for patients with metastatic pancreatic cancer that has progressed after receiving gemcitabine treatment. This is the first time that the Group has submitted a new drug marketing application for complex liposome-encapsulated anti-cancer chemotherapy in the US.

Important matters

$CHINA QINFA (00866.HK)$Began operating SDE coal mine

$CITIC RESOURCES (01205.HK)$: AWAC allowed to continue bauxite mining and downstream alumina refining in Western Australia

$CITIC (00267.HK)$: CITIC Deca proposes a spin-off and an independent listing on the Shanghai Stock Exchange

$SWHY (06806.HK)$: Completed the issuance of 5 billion yuan of short-term corporate bonds

$BOSIDENG (03998.HK)$: The conversion price of US$275 million 1.00% convertible bonds due 2024 was adjusted to HK$4.01 per share

$NORTH MINING (00433.HK)$: Proposed acquisition of some shares in 4 Guangxi companies

Pharmaceutical Innovation

$SIRNAOMICS-B (02257.HK)$: An application for clinical trials of RV-1770, an innovative mRNA vaccine against human respiratory syncytial virus (RSV), was approved by the FDA

$FUDANZHANGJIANG (01349.HK)$: Aminovaleric acid hydrochloride granules are used to visualize bladder cancer surgery to obtain a notice of acceptance of drug clinical trial applications

$GRANDPHARMA (00512.HK)$Affiliated to enter into a distribution agreement with Sirtex Medical

$BIOCYTOGEN-B (02315.HK)$Antibody agreement reached with Ona Therapeutics for ADC development for solid tumors

Repurchase cancellation

$TENCENT (00700.HK)$On December 18, 1.29 million shares were repurchased at a cost of HK$401 million

$AIA (01299.HK)$Repurchase of 1.99 million shares at a cost of HK$134 million on December 18

$LI NING (02331.HK)$Repurchase of 6.1 million shares at a cost of HK$114 million on December 18

$WUXI BIO (02269.HK)$On December 18, 782 million shares were repurchased at a cost of HK$22.8877 million

$KUAISHOU-W (01024.HK)$On December 18, 400,000 shares were repurchased at a cost of HK$2.06 million

$MGM CHINA (02282.HK)$On December 18, 586,100 shares were repurchased at a cost of HK$5.7616 million

$KINGSOFT (03888.HK)$On December 18, 190,000 shares were repurchased at a cost of HK$4.67 million

$SKYWORTH GROUP (00751.HK)$Repurchase of 1 million shares at a cost of HK$2,827,000 on December 18

Editor/Corrine